Viewing records where tag name contains "media" View All

Starpharma (ASX:SPL) to relaunch VIRALEZE treatment in UK

Apr 1st, 2022

The Market Herald features Starpharma following its latest announcement related to the relaunch of VIRALEZE™ in the UK.

Read More

Active agent in Australian-developed nasal spray highly active against 'Omicron'

Mar 2nd, 2022

Australian biotechnology and life sciences media platform, BiotechDispatch, featured the news of Starpharma's latest announcement regarding SPL7013's virucidal activity against Omicron.

Read More

Starpharma’s (ASX:SPL) nasal spray outperforms competitors against Omicron variant

Mar 1st, 2022

"Starpharma’s (SPL) antiviral nasal spray has achieved a greater than 99.5 per cent reduction of virus infectivity against the Omicron variant of SARS-CoV-2." The Market Herald reports on Starpharma, following the company's latest announcement. 

Read More

Starpharma (ASX:SPL) pens distribution deal in Saudi Arabia

Feb 3rd, 2022

The Market Herald reports on Starpharma's new partnership with Etqan & Nazahah for the sales and distribution of VIRALEZE™ in Saudi Arabia. 

Read More

Starpharma’s (ASX:SPL) December quarter boosted by VIRALEZE success

Jan 28th, 2022

The Market Herald reports on Starpharma, following the release of the company's Quarterly Cashflow and Activities Report.

Read More

Australian homegrown COVID-19 pipeline shows signs of maturity

Jan 27th, 2022

Starpharma's CEO Dr Jackie Fairley was interviewed by BioWorld about the company's antiviral nasal spray VIRALEZE™.

Read More

Starpharma announces early orders following Vietnam distribution agreement

Dec 14th, 2021

BiotechDispatch report on Starpharma's latest announcement related to the launch of VIRALEZE™ in Vietnam. 

Read More

Starpharma (ASX:SPL) tables $2m in Vietnam VIRALEZE orders

Dec 13th, 2021

"Since October, pharmaceutical company Starpharma (SPL) has received VIRALEZE orders totaling more than $2 million for Vietnam", as reported in The Market Herald.

Read More

Novel Cabazitaxel Formulation Shows Promise for Metastatic Prostate Cancer

Nov 30th, 2021

Targeted Oncology features Starpharma's latest DEP® announcement - the release of positive interim results from the prostate cancer cohort of Starpharma's ongoing phase 2 trial of DEP® cabazitaxel.

Read More

Starpharma reports positive interim results from Phase 2 DEP cabazitaxel study in prostate cancer

Nov 27th, 2021

Starpharma's positive interim results from its ongoing phase 2 trial of DEP cabazitaxel featured in Seeking Alpha. 

Read More

Starpharma Releases Positive DEP® Phase 2 Interim Results In Prostate Cancer

Nov 27th, 2021

British Herald reports on Starpharma's announcement, regarding the positive interim results from the prostate cancer cohort in its ongoing phase 2 trial of DEP® cabazitaxel.

Read More

Starpharma Announces Encouraging Interim Results for Prostate Cancer Drug

Nov 27th, 2021

Gene Online reports on the news of Starpharma's latest announcement - the release of positive interim results from the prostate cancer cohort of Starpharma's ongoing phase 2 trial of DEP® cabazitaxel. 

Read More

Starpharma (ASX:SPL) continues VIRALEZE success in December quarter

Oct 29th, 2021

"Starpharma (SPL) has released its September quarterly report, with the quarter again highlighted by the continued success of VIRALEZE," as reported by The Market Herald. 

Read More

Starpharma signs distribution agreement for antiviral in Vietnam

Oct 26th, 2021

News of Starpharma signing an initial supply contract for VIRALEZE™ in Vietnam featured in BiotechDispatch. Read the article here

Read More

Starpharma (ASX:SPL) signs VIRALEZE supply deal for Vietnam

Oct 26th, 2021

The Market Herald features news of Starpharma's latest supply arrangement for VIRALEZE™ in Vietnam.

Read More

Nanotechnology Offers New Ways To Fight An Endless Pandemic

Oct 18th, 2021

Starpharma's VIRALEZE™ antiviral nasal spray was featured in Report Wire.

Read More

Nanotechnology offers alternative ways to fight COVID-19 pandemic with antivirals

Oct 14th, 2021

Starpharma's VIRALEZE™ antiviral nasal spray was featured in the October issue (VOL 39) of Nature Biotechnology

Read More

Starpharma (ASX:SPL) launches nasal spray into Italian market

Oct 8th, 2021

The Market Herald features news of Starpharma's latest distribution agreement for VIRALEZE™ antiviral nasal spray in Italy. 

Read More

Starpharma (ASX:SPL) shows 99.99pc antiviral activity against Delta COVID-19 variant

Jul 27th, 2021

"Starpharma's (SPL) SPL7013 drug has shown a reduction of more than 99.99 per cent against the Delta variant of SARS-CoV-2," The Market Herald reports. Read the full article here.  Read More

COVID-19: Viraleze Nasal Spray Highly Effective Against Alpha, Beta And Gamma Variants

Jun 19th, 2021

"New data released on June 18 showed that Australia’s Viraleze anti-COVID nasal spray is more than 99.99 per cent effective against three of the four variants of the SARS-CoV-2 virus," as reported by Republic World. Read the full article here.

Read More

Latest Testing Confirms Viraleze Highly Effective Against Alpha, Beta and Gamma COVID Variants

Jun 18th, 2021

News18 reports on Starpharma's latest VIRALEZETM announcement: "New data released today shows that Australia’s Viraleze anti-COVID nasal spray is more than 99.9% effective against three of the four deadliest variants of the SARS-CoV-2 virus." Read the full article here.

Read More

Latest testing confirms Viraleze highly effective against Alpha, Beta and Gamma COVID variants

Jun 18th, 2021

Markets Insider features Starpharma's latest announcement, ..."The results hold significant promise for Viraleze™ – developed by Melbourne-based biopharmaceutical company Starpharma (ASX: SPL) – in the fight against new and emerging variants of SARS-CoV-2, as several countries begin their long-awaited opening of international borders..." Read the full article here

Read More

Latest testing confirms Viraleze highly effective against Alpha, Beta and Gamma COVID variants

Jun 18th, 2021

"New data released today shows that Australia's Viraleze™ anti-COVID nasal spray is more than 99.9% effective against three of the four deadliest variants of the SARS-CoV-2 virus," as reported by the New Delhi Times. Read the full article here.

Read More

Starpharma (ASX:SPL) shows 99.9pc antiviral activity against three COVID-19 variants

Jun 18th, 2021

"Starpharma's (SPL) SPL7013 drug has shown a reduction of more than 99.9 per cent against the Alpha, Beta and Gamma SARS-CoV-2 variants," The Market Herald reports. Read the full article here.

Read More

Scripps Research Institute testing shows Viraleze highly active against UK COVID strain

Jun 1st, 2021

Markets Insider featured Viraleze and Starpharma following the announcement of SPL7013's potent antiviral activity against the UK coronavirus variant. Read the full article here

Read More

Starpharma (ASX:SPL)'s nasal spray achieves 98% efficacy against COVID-19

Jun 1st, 2021

"Biopharmaceutical company Starpharma (ASX:SPL) claims the company’s nasal spray product is a highly efficacious means of protection from the UK variant of the coronavirus," Finance News Network reports. Read the full article here

Read More

Starpharma (ASX:SPL) shows 98pc antiviral activity against U.K COVID-19 variant

Jun 1st, 2021

The Market Herald reports on Starpharma's latest announcement: "Starpharma (SPL) has confirmed that its SPL7013 drug has potent antiviral activity against the U.K. SARS-CoV-2 variant.

"In laboratory studies, SPL7013 achieved a reduction of more than 98 per cent against the virus."

Read the full article here. 

Read More

Tackling Covid: How the Harlequins are defending themselves

May 22nd, 2021

Twickenham Nub News interviewed Harlequins’ Head of Medical Services, Mike Lancaster, about the partnership with Viraleze. "The Harlequins’ long-awaited return to Twickenham Stoop has seen the team make many changes to ensure players’ safety.

"Alongside several changes at the stadium, the team has also started defending itself with a new nose spray, Viraleze." Read the full article here. 

Read More

Tax incentives to encourage innovation

May 18th, 2021

Dr Jackie Fairley, CEO of Starpharma discusses the Australian governments proposals for a 'patent box' and what it will mean for the company and Australian innovation in general. Watch here. (ausbiz account required)

Read More

Harlequins Partners with Anti-Viral Nasal Spray Viraleze

May 11th, 2021

Sport Industry Group featured the announcement of Starpharma's VIRALEZETM partnership with Harlequins. "Harlequins has announced a new partnership with antiviral nasal spray VIRALEZETM, which the club says it will use as one part of its suite of measures put in place to help protect its players and coaching staff." Read more here.

Read More

Harlequins Partners Antiviral Nasal Spray Brand Viraleze

May 11th, 2021

iSportconnect reported on the new partnership between Starpharma's antiviral nasal spray, VIRALEZETM, and Harlequins, a professional rugby union team in the UK. Read more here

Read More

Starpharma (ASX:SPL) launches antiviral nasal spray in Europe

May 6th, 2021

The Market Herald reported on Starpharma's launch of VIRALEZE™  in Europe. Read the full article here.

  • Starpharma’s (SPL) antiviral nasal spray is now available for purchase by consumers in Europe via the company’s online store
  • VIRALEZE is a broad spectrum antiviral nasal spray, which studies have shown can inactivate more than 99.9 per cent of coronavirus pathogens within one minute
  • The product is already available online in the U.K. and through Lloyds Pharmacy’s 1400 stores, with the company now pursuing avenues to provide rapid access for VIRALEZE in India
  • Starpharma shares are up 3.93 per cent, trading at $1.85

 

Read More

Australian company develops a $27 anti-viral nasal spray that 'deactivates' Covid - and it's being used right across the UK

May 4th, 2021

Eliza McPhee for Daily Mail Australia reported: An Australian biotech company has joined the fight against coronavirus by launching an anti-viral nasal spray that's already available in the UK. Read the article here

  • Biotech company Starpharma has launched anti-viral nasal spray in the UK
  • It acts as a barrier to coronavirus, trapping it in the nose and inactivating virus
  • Spray best used once every six hours for up to 30 days, CEO Jackie Fairley says
  • Melbourne-based company says it has plans to launch product soon in Australia 
Read More

Starpharma (ASX:SPL) spends March quarter developing VIRALEZE

Apr 28th, 2021

Starpharma featured in The Market Herald following the announcement of Starpharma's Quarterly Cashflow and Activities Report. Read more here

Read More

GlaxoSmithKline hoping to deliver Australia’s next COVID treatment

Apr 16th, 2021

Starpharma featured in The Sydney Morning Herald's daily COVID-19 update, as reported by Emma Koehn: ASX-listed companies have pivoted swiftly towards virus treatments and preventative in the past year, including Melbourne-based Starpharma which successfully brought a nasal spray to market in the UK last month. Read more here

Read More

Aussie virus killer not to be sneezed at

Apr 11th, 2021

The Australian interviewed Dr Jackie Fairley, Starpharma CEO, about the recent launch of Viraleze in the UK. "As the nation hyperventilates over a delay in the vaccine rollout, Starpharma is rolling out a new line of defence against the coronavirus in global markets." Read more here. (Behind paywall)

Read More

LloydsPharmacy launches nasal spray designed to fight coronavirus

Mar 30th, 2021

The Grocer reported on the launch of VIRALEZE in LloydsPharmacy across the UK. It launches online this week, ahead of an in-store rollout from April. Read more here.

Read More

Covid antiviral nasal spray available from Lloyds

Mar 30th, 2021

Pharmacy Magazine UK reported on the launch of VIRALEZE in the UK. A novel nasal spray available exclusively from LloydsPharmacy. The UK will be the first country to launch this product. Read more here.

Read More

Lloyds Pharmacy offering first-ever Covid nasal spray Viraleze that 'blocks 99.9% of germs'

Mar 30th, 2021

CambridgeshireLive featured news of the VIRALEZE launch in the UK. A groundbreaking Covid nasal spray called Viraleze is now available to buy online. Lloyds Pharmacy is rolling out the UK's first-ever nasal spray specifically designed to fight coronavirus. Read more here

Read More

VIRALEZE™ featured on Sky News

Mar 29th, 2021

Sky News interviewed Starpharma CEO Dr Jackie Fairley upon launch of VIRALEZE™ at LloydsPharmacy in the UK. Dr George Kinghorn, Infectious Disease Adviser and former Clinical Director of the Sheffield Teaching Hospitals NHS Foundation Trust was also interviewed for further commentary on VIRALEZE™.

 

Read More

Starpharma to launch anti-COVID nasal spray with major UK pharmacy chain

Mar 25th, 2021

Business News Australia reported VIRALEZE will be stocked by LloydsPharmacy in the UK. It will first be made available at LloydPharmacy's online store and is expected to be instore in April. Read more here.

Read More

Aussie biotech Starpharma signs deal to sell COVID nose spray in Britain

Mar 25th, 2021

The Age reported Australian biotech Starpharma is taking its COVID-fighting antiviral nasal spray to the world, signing a deal with UK chemist chain LloydsPharmacy to sell the product in Britain as the country emerges from lockdown. Read more here

Read More

Starpharma (ASX:SPL) reports DEP HER2-lutetium shows potent anticancer effect

Mar 16th, 2021

Finance News Network reported that Starpharma's second radiopharmaceutical candidate, DEP HER2-lutetium, achieved potent and durable anticancer activity, with complete tumour regression, outperforming Herceptin labelled with lutetium, in a breast cancer model. Read more here

Read More

Starpharma (ASX:SPL) shares rise on breast cancer development

Mar 16th, 2021

The Market Herald reported that Starpharma's second radiopharmaceutical candidate, DEP HER2-lutetium, had achieved anti-cancer activity in breast cancer, and that the drug outperformed Herceptin, a treatment for a type of breast cancer called HER2 positive. Read more here

Read More

Starpharma Up With News, Down With None; Timing Entry Makes Sense

Feb 25th, 2021

Seeking Alpha, a financial market portal featured an update Starpharma, including the European registration of its VIRALEZE™ antiviral nasal spray. To read the full article click here.

Read More

Channel 7 News reports Starpharma's VIRALEZE has been registered in the UK/Europe

Feb 23rd, 2021

Channel 7 News (Melbourne) reports Starpharma's VIRALEZE™ has been registered in the UK/Europe. Watch here

Read More

Starpharma signs research agreement with MSD

Feb 12th, 2021

The Market Herald reported that Starpharma signed a Research Agreement with Merck & Co., Inc., Kenilworth NJ USA for dendrimer-based Antibody Drug Conjugates (ADCs) utilising Starpharma’s proprietary DEP® technology. Read more here

Read More

Ausbiz interviews Starpharma CEO Dr Jackie Fairley

Feb 10th, 2021

Finance and market news website AusBiz interviewed Starpharma CEO Dr Jackie Fairley to discuss the global expansion of AstraZeneca’s clinical trial for AZD0466 and their multi-product DEP® licence with Starpharma. She also spoke about the upcoming launch of VIRALEZE in Europe. Watch the interview here.

 

Read More

Aussie condom antiviral recruited for Covid-19 fight

Feb 4th, 2021

The Australian interviewed Starpharma CEO Dr Jackie Fairley regarding Starpharma’s plans for the European launch of VIRALEZE™ antiviral nasal spray. Read article here.

Read More

Australian-developed COVID nasal spray set to land in Europe

Feb 4th, 2021

Biotech Dispatch reported on Starpharma's launch plans for VIRALEZE™ in Europe. Read the full article here.

Read More